Budapest, Hungary

Zoltan Torma

This inventor holds 1 USPTO granted patent, plus 1 CIPO patent. Top assignee: Egis Gyogyszergyar. Active years: 1992.


% Patents Active = 100.0


Average Co-Inventor Count = 12.0

ph-index = 1

Forward Citations = 15(Granted Patents)


Company Filing History:


Years Active: 1992

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Zoltan Torma: Innovator in Pharmaceutical Composition

Introduction

Zoltan Torma is a notable inventor based in Budapest, Hungary. He has made significant contributions to the field of pharmaceuticals, particularly in the development of solid pharmaceutical compositions. His work has led to advancements in drug formulation and delivery systems.

Latest Patents

Zoltan Torma holds a patent for a solid pharmaceutical composition and a process for preparing the same. The patent focuses on a regulated release solid pharmaceutical composition that includes 4-(2'-nitro-phenyl)-2,6-dimethyl-3,5-dimethoxycarbonyl-1,4-dihydro-pyridine, commonly known as nifedipine. The process involves admixing a solution of nifedipine with hydrophilizing agents and retarding agents, applying the solution onto an inert carrier, and subsequently compressing the mixture into tablets or filling it into capsules.

Career Highlights

Throughout his career, Zoltan Torma has worked with prominent companies in the pharmaceutical industry, including Egis Gyógyszergyár and Jozsef Kenderfi. His experience in these organizations has contributed to his expertise in drug formulation and development.

Collaborations

Zoltan has collaborated with several professionals in his field, including Peter Tompe and Attila Mandi. These collaborations have likely enhanced his research and development efforts in pharmaceutical innovations.

Conclusion

Zoltan Torma's contributions to the pharmaceutical industry through his innovative patent and collaborations highlight his role as a significant inventor. His work continues to impact the field of drug formulation and delivery.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…